Multimodal “4D”-therapy of pediatric high grade glioma

Introduction

Paediatric high grade glioma (pHGG) is the most common malignant childhood brain tumour, with standard-of-care inevitably resulting in therapy-resistant relapse or disease progression. The need for new combinatorial treatments is universally acknowledged; however, modern combination therapies are sparse, include at most two modalities, and have so far not been able to significantly improve the dismal prognosis of the disease.

Proposed Strategy

In this proposal, I conceptualize a highly targeted multimodal treatment strategy for pHGG (4D-therapy) based on complementary precision medicine approaches. The system leverages multiple inter-modal synergies, overcomes resistance to individual therapies, and disperses off-targeting to different cell populations, thereby creating a large therapeutic window.

Initial Screening

Initially, we will conduct a comprehensive screen to evaluate a novel regimen of combined upfront targeted drug- and radiotherapy (RT), followed by functional validation in vitro and in vivo. In-depth molecular profiling will allow us to unravel mechanisms of radiosensitization.

Gene Therapy Approach

Further, we aim to establish an innovative gene therapy approach with unprecedented, highly specific tropism for tumour cells by combining elaborately selected adeno-associated viruses and nanocapsules with newly identified Cas-nucleases.

Systematic Combination

Ultimately, we will systematically combine drug-RTs, gene therapies, and existing tumour-specific CAR-T cells within a rationally designed, multimodal treatment regimen and evaluate its efficacy in a series of preclinical studies.

Predictive Power

A broad representation of patient-derived xenografts, complemented by immunocompetent allograft models, will provide leading-edge predictive power and a unique dataset to investigate multimodal interactions.

Expected Outcomes

I expect this project to provide pioneering insights into inter-modal treatment synergies, to produce stratified treatment protocols for pHGG, directly informing clinical trials, and to become a pathbreaking feasibility study for multimodal cancer therapy.